A hydroxyquinoline carrying a single hydroxy substituent.
ChEBI ID: 38775
| Member | Definition | Role |
|---|---|---|
| 2-(n-heptyl)-4-hydroxyquinoline n-oxide | 2-heptyl-1-hydroxy-4(1H)-quinolinone | |
| 2,8-dihydroxyquinoline | 8-hydroxyquinolin-2(1H)-one; quinoline-2,8-diol | |
| 4-hydroxyquinoline | A monohydroxyquinoline carrying a hydroxy group at position 4. | 4-quinolone; quinolin-4-ol |
| 6-hydroxyquinoline | A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 6. | quinolin-6-ol |
| 7-hydroxyquinoline | A monohydroxyquinoline carrying a hydroxy substituent at position 7. | quinolin-7-ol |
| 8-hydroxyquinoline N-oxide | A quinoline N-oxide carrying a hydroxy substituent at position 8. | 8-hydroxyquinoline N-oxide |
| carbostyril | A monohydroxyquinoline carrying a hydroxy substituent at position 2. It is an intermediate metabolite produced duting the microbial degradation of quinoline. | quinolin-2-ol; quinolin-2(1H)-one |
| chloroxine | A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 have been substituted by chlorine. A synthetic antibacterial prepared by chlorination of quinolin-8-ol, it is used for the treatment of dandruff and seborrhoeic dermatitis of the scalp. | chloroxine |
| chlorquinaldol | A monohydroxyquinoline that is quinolin-8-ol which is substituted by a methyl group at position 2 and by chlorine at positions 5 and 7. An antifungal and antibacterial, it was formerly used for topical treatment of skin conditions and vaginal infections. | chlorquinaldol |
| clioquinol | A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease. | 5-chloro-7-iodoquinolin-8-ol |
| indacaterol | A monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary disease. | indacaterol |
| iodoquinol | A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine. It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis. | iodoquinol |
| kynurenic acid | A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4. | kynurenic acid |
| my 12-62c | A monohydroxyquinoline that is 4-hydroxyquinoline bearing an additional heptyl substituent at position 2. | 2-heptyl-4-hydroxyquinoline; 2-heptyl-4-quinolone |
| nitroxoline | A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5. | nitroxoline |
| oxyquinoline | A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes. | quinolin-8-ol |
| quinolobactin | A quinolinemonocarboxylic acid that is xanthurenic acid in which the hydroxy group at position 4 is replaced by a methoxy group. It is a siderophore isolated from Pseudomonas fluorescens ATCC 17400. | quinolobactin |
| xanthurenic acid 8-methyl ether | A quinolinemonocarboxylic acid that is kynurenic acid which is substituted by a methoxy group at position 8. | 4-hydroxy-8-methoxyquinaldic acid |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2,575 (14.30) | 18.7374 |
| 1990's | 3,516 (19.52) | 18.2507 |
| 2000's | 4,289 (23.81) | 29.6817 |
| 2010's | 5,940 (32.98) | 24.3611 |
| 2020's | 1,691 (9.39) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,568 (8.09%) | 5.53% |
| Reviews | 1,743 (9.00%) | 6.00% |
| Case Studies | 1,018 (5.25%) | 4.05% |
| Observational | 91 (0.47%) | 0.25% |
| Other | 14,957 (77.19%) | 84.16% |